Figure 3.

RV16 stimulation enhances NK cell CD107a expression, and this is attenuated by blocking of IFN-I signaling. PBMCs from healthy people (n=12) were cultured in vitro with B18R (100 ng/ml) for 1 h, alongside a media-only control (UT), prior to stimulation with RV16 (MOI = 1), alongside an unstimulated control (US) for 24 h. (A) Percentage of degranulating (CD107a+) CD56⁺ (left), CD56^dim (middle), and CD56^bright (right) NK cells. (B) Level of surface expression (indicated by MFI) of the degranulation marker (CD107a) on CD56⁺ (left), CD56^dim (middle), and CD56^bright (right) NK cells. (C) Frequency and MFI of CD107a⁺ CD56^bright NK cells. Each colored symbol represents data from one donor, lines represent medians. Data are representative of three experiments. *p<0.05, **p<0.01 by Wilcoxon matched-pairs signed rank tests. IFN-I, type I interferon; NK, natural killer; RV16, rhinovirus 16; PBMC, peripheral blood mononuclear cell; UT, untreated; MOI, multiplicity of infection; US, unstimulated; MFI, median fluorescence intensity.